Life Bio teams up with Singapore researchers to leverage partial epigenetic reprogramming platform across ‘multiple organ systems.’
Longevity biotech Life Biosciences has entered into a research collaboration with the SingHealth Duke-NUS Regenerative Medicine Institute of Singapore (REMEDIS), aimed at advancing cellular rejuvenation therapies. The partnership represents a strategic expansion of Life Bio’s efforts to address age-related diseases by leveraging its proprietary partial epigenetic reprogramming platform, and aims to help broaden the application of the approach across multiple organ systems.
Hailing Singapore as a “global leader in healthy aging,” Life Bio CEO Jerry McLaughlin said “By combining REMEDIS’s biological and translational expertise with our partial epigenetic reprogramming platform, we have a powerful opportunity to accelerate development of novel therapeutics to reverse and prevent a wide range of age-related diseases.”
REMEDIS focuses on regenerative approaches to treat age-related and chronic diseases by regenerating diseased cells, tissues and organs. The institute concentrates on seven key areas: musculoskeletal diseases, bone marrow conditions, blood disorders, cardiovascular diseases, acute and chronic wound healing, neurosensory disorders and retinal and corneal diseases.
“Our collaboration aims to pioneer targeted treatments for age-related diseases and chronic conditions, opening new possibilities for transformative patient care,” said REMEDIS co-director Professor William Hwang.
Life Bio is harnessing epigenetic reprogramming to restore cellular function to a more youthful state, employing three key transcription factors to epigenetically restore older and damaged cells to a more youthful state. The approach aims to address the underlying drivers of aging to intervene in a wide array of degenerative conditions.
The company’s lead therapeutic candidate, ER-100, is being developed to treat conditions including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), and the first ever human trials of a partial epigenetic reprogramming therapy now expected to begin in early 2026. In parallel, Life Biosciences is expanding its pipeline to include additional age-associated diseases, which will also be the focus of the new partnership.
Among REMEDIS’s accomplishments is the development of laminin-based technologies capable of expanding clinically relevant cells from the heart, eye and skin. In addition, the institute is advancing therapies for osteoarthritis through the use of autologous mesenchymal stem cell-based cartilage repair, as well as exploring treatments for sarcopenia and blood cancers through the expansion of blood and immune cells.
“This collaboration reflects our belief that aging is a universal process that can be treated, which offers opportunities for interventions that may help address multiple age-related diseases,” said Harvard professor and Life Bio co-founder Dr David Sinclair.
